Pegcetacoplan
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
C3G
Conditions
C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Trial Timeline
Nov 12, 2021 → Jan 14, 2025
NCT ID
NCT05067127About Pegcetacoplan
Pegcetacoplan is a phase 3 stage product being developed by Apellis Pharmaceuticals for C3G. The current trial status is completed. This product is registered under clinical trial identifier NCT05067127. Target conditions include C3G, IC-MPGN, C3 Glomerulopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04729062 | Pre-clinical | Completed |
| NCT07020832 | Phase 3 | Recruiting |
| NCT06161584 | Pre-clinical | Active |
| NCT05809531 | Phase 3 | Active |
| NCT05067127 | Phase 3 | Completed |
| NCT04572854 | Phase 2 | Active |
| NCT04901936 | Phase 2 | Recruiting |
| NCT03531255 | Phase 3 | Active |
| NCT03593200 | Phase 2 | Completed |
| NCT03465709 | Phase 1/2 | Terminated |
| NCT02588833 | Phase 1 | Completed |
| NCT02503332 | Phase 2 | Completed |
| NCT02264639 | Phase 1 | Completed |
| NCT02461771 | Phase 1 | Completed |
Competing Products
6 competing products in C3G
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan | Novartis | Pre-clinical | 23 |
| Placebo + iptacopan | Novartis | Phase 3 | 77 |
| Avacopan + Avacopan Matching Placebo | Amgen | Phase 2 | 51 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 2 | 47 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 18 |